The Company announced that the USPTO has issued a Notice of Allowance for Aeterna’s U.S. patent application No. 17/375,709 titled, "Use of Macimorelin in Assessing Growth Hormone Deficiency in Children." The Company anticipates the issue of the formal registration of this U.S. patent application in the coming months. AEZS-130-P02, Aeterna’s pivotal Phase 3 safety and efficacy study evaluating macimorelin for the diagnosis of CGHD, remains ongoing. Most clinical sites in the U.S. as well as European countries are open for patient recruitment.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AEZS:
- Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
- Aeterna Zentaris reports Q4 revenue $2.5M vs. $1M last year
- Aeterna Zentaris announces Pharmanovia has acquired rights to GHRYVELIN
- Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)